AR and prostate cancer: In our previous study, we showed that vortioxetine did not directly promote the growth of either androgen-dependent or -independent prostate cancer cells in vitro, and did not interfere with the anti-proliferative activity of the androgen-receptor antagonist enzalutamide [14].